Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug.
Due to chloroquine resistance, several African countries have changed their first-line malaria treatment to sulfadoxine-pyrimethamine (SP). In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.
Fairhurst
R M
RM
Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. rfairhurst@niaid.nih.gov
Sadou
B
B
Guindo
A
A
Diallo
D A
DA
Doumbo
O K
OK
Wellems
T E
TE
D000962:Antimalarials / Q000009:adverse effects*; D004338:Drug Combinations; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D011739:Pyrimethamine / Q000009:adverse effects*; D013413:Sulfadoxine / Q000009:adverse effects*
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine